MA50435A - Anticorps anti-ligand anti-cd40 thérapeutiques - Google Patents

Anticorps anti-ligand anti-cd40 thérapeutiques

Info

Publication number
MA50435A
MA50435A MA050435A MA50435A MA50435A MA 50435 A MA50435 A MA 50435A MA 050435 A MA050435 A MA 050435A MA 50435 A MA50435 A MA 50435A MA 50435 A MA50435 A MA 50435A
Authority
MA
Morocco
Prior art keywords
antibodies
ligand
therapeutic
therapeutic anti
ligand anti
Prior art date
Application number
MA050435A
Other languages
English (en)
Inventor
Alexey Lugovskoy
Original Assignee
Als Therapy Development Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst filed Critical Als Therapy Development Inst
Publication of MA50435A publication Critical patent/MA50435A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050435A 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques MA50435A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762510471P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
MA50435A true MA50435A (fr) 2020-09-02

Family

ID=63592816

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050435A MA50435A (fr) 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques

Country Status (14)

Country Link
US (2) US11384152B2 (fr)
EP (1) EP3630843A2 (fr)
JP (3) JP7766392B2 (fr)
KR (1) KR102840867B1 (fr)
CN (2) CN117843789A (fr)
AU (2) AU2018271915B2 (fr)
CA (1) CA3063730A1 (fr)
GB (1) GB2578037A (fr)
IL (3) IL322942A (fr)
MA (1) MA50435A (fr)
MX (1) MX2023004314A (fr)
RU (2) RU2022108410A (fr)
SG (1) SG10202111207TA (fr)
WO (1) WO2018217918A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3630843A2 (fr) * 2017-05-24 2020-04-08 ALS Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques
DK3993876T3 (en) * 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2025518096A (ja) * 2022-05-27 2025-06-12 エレドン ファーマシューティカルズ，インコーポレイテッド 筋萎縮性側索硬化症の治療方法
WO2024211211A1 (fr) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Méthodes pour améliorer la survie d'une greffe à l'aide d'anticorps à chaîne gamma du récepteur il-2
KR20260116248A (ko) 2023-11-28 2026-07-28 엘레던 파마슈티컬즈, 아이엔씨. 이식 거부반응 예방을 위한 방법 및 조성물
WO2025235670A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Utilisation d'anticorps anti-ligand cd40 pour l'immunosuppression dans une transplantation de cellules d'îlots
WO2025235683A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Procédés et compositions pour la prévention du rejet de greffe
WO2026092377A1 (fr) * 2024-10-28 2026-05-07 信达生物制药(苏州)有限公司 Traitement d'une maladie auto-immune à l'aide d'un anticorps anti-cd40l
CN119823269B (zh) * 2024-12-10 2025-11-07 上海交通大学医学院附属瑞金医院 Cd40配体的抗原表位肽、抗体及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN1572325A (zh) 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
SK156099A3 (en) 1997-05-17 2000-06-12 Biogen Inc Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
CN100352497C (zh) 1998-04-03 2007-12-05 达特茅斯学院理事 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
KR20020072277A (ko) 1999-11-08 2002-09-14 아이덱 파마슈티칼즈 코포레이션 항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001083755A2 (fr) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004037204A2 (fr) 2002-10-25 2004-05-06 University Of South Florida Methodes et composes de perturbation de la signalisation cd40r/cd40l dans le traitement de la maladie d'alzheimer
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
WO2005003174A1 (fr) 2003-07-08 2005-01-13 Genesto A/S Element de liaison a une proteine a d'adhesine de surface pneumocoque
JP4944608B2 (ja) 2003-07-26 2012-06-06 バイオジェン・アイデック・エムエイ・インコーポレイテッド 改良された抗原結合親和性を有する、変更された抗体
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) * 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006138316A2 (fr) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methodes permettant d'administrer des molecules au systeme nerveux central
AU2006315274B2 (en) 2005-11-17 2012-07-05 Biogen Ma Inc. Platelet aggregation assays
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7647438B1 (en) 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
AU2009272771B2 (en) * 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (fr) 2008-12-05 2017-11-01 ALS Therapy Development Institute Méthode pour le traitement des maladies neurodegeneratives
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2625203A1 (fr) * 2010-10-05 2013-08-14 Novartis AG Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
WO2012103218A1 (fr) 2011-01-25 2012-08-02 University Of South Florida Modèle transgénique de la maladie d'alzheimer
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
WO2012138768A2 (fr) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anticorps anti-cd154 ayant une liaison détériorée au fcr et/ou des propriétés de liaison au complément détériorée et leur utilisation dans des thérapies immunologiques
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
NO2699601T3 (fr) 2011-04-21 2018-06-16
WO2013033008A2 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques à fc en tandem
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
MX355234B (es) 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
CN105121621B (zh) 2012-10-18 2019-08-02 张永新 用于细胞动静态交替培养的生物反应器系统及其方法
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US20170051059A1 (en) * 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
WO2015164595A1 (fr) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Utilisation d'un composé ctla4 pour obtenir une rémission sans médicament chez des sujets atteints de pr précoce
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3630843A2 (fr) * 2017-05-24 2020-04-08 ALS Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques

Also Published As

Publication number Publication date
WO2018217918A3 (fr) 2019-01-17
SG10202111207TA (en) 2021-11-29
WO2018217918A2 (fr) 2018-11-29
US12617859B2 (en) 2026-05-05
CN110662768A (zh) 2020-01-07
KR20200010294A (ko) 2020-01-30
IL270729B1 (en) 2025-10-01
CN117843789A (zh) 2024-04-09
RU2019143098A (ru) 2021-06-24
GB201918703D0 (en) 2020-01-29
IL309444A (en) 2024-02-01
GB2578037A (en) 2020-04-15
JP2026050358A (ja) 2026-03-19
RU2770209C2 (ru) 2022-04-14
IL270729A (en) 2020-01-30
JP2020521745A (ja) 2020-07-27
RU2019143098A3 (fr) 2021-09-20
AU2018271915B2 (en) 2025-03-27
CN110662768B (zh) 2024-01-30
IL309444B2 (en) 2026-02-01
CA3063730A1 (fr) 2018-11-29
IL322942A (en) 2025-10-01
JP2023065390A (ja) 2023-05-12
AU2025204772A1 (en) 2025-07-17
US20200223932A1 (en) 2020-07-16
JP7766392B2 (ja) 2025-11-10
RU2022108410A (ru) 2022-04-05
US11384152B2 (en) 2022-07-12
KR102840867B1 (ko) 2025-07-30
EP3630843A2 (fr) 2020-04-08
IL309444B1 (en) 2025-10-01
US20230048260A1 (en) 2023-02-16
AU2018271915A1 (en) 2019-11-28
IL270729B2 (en) 2026-02-01
MX2023004314A (es) 2023-05-04

Similar Documents

Publication Publication Date Title
FR25C1022I2 (fr) Anticorps anti-pd-1
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3423089A4 (fr) Anticorps anti-tigit
MA49749A (fr) Anticorps anti-cd137
EP3334757A4 (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3297671A4 (fr) Anticorps anti-ror1
EP3507307A4 (fr) Anticorps bispécifiques
MA46272A (fr) Anticorps anti-cd27
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3383915A4 (fr) Anticorps anti-pd-1
MA47472A (fr) Anticorps
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3617231A4 (fr) Anticorps anti-gpc-1
IL270729A (en) Therapeutic anti-cd40 ligand antibodies
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine